Noninvasive Vagus Nerve Stimulation for Migraine Treatment: The PRESTO Study

News
Slideshow

Noninvasive vagus nerve stimulation may be a viable method for the treatment of acute episodic migraine, according to a new study.

Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
Early Menopause Was Associated with Increased Risk of Cognitive Decline, Depression within 2 Years / image credit Miharu Nakanishi, PhD Courtesy of World Dementia Council

Early Menopause Was Associated with Increased Risk of Cognitive Decline, Depression within 2 Years

Grace Halsey
April 22nd 2025
Article

The findings suggest that women who experience early menopause (age <40 vs >50 years) may constitute a sex-specific high-risk group for cognitive decline.

Distress Signals: How to Help a Clinician Colleague in Need

Distress Signals: How to Help a Clinician Colleague in Need

Sydney Jennings
February 14th 2023
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention

FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention

Grace Halsey
April 16th 2025
Article

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Gantenerumab May Delay Alzheimer Disease Symptoms in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Gantenerumab May Delay Alzheimer Disease Symptoms in High-Risk Adults: Daily Dose

Sydney Jennings
April 10th 2025
Article

Your daily dose of the clinical news you may have missed.

Real-World Lecanemab Data Presented at AD/PD 2025 Confirms Clinical Trial Findings

Eisai Presents Real-World Lecanemab Data at AD/PD 2025 Confirming Phase 3 Clinical Trial Findings

Grace Halsey
April 8th 2025
Article

In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.

© 2025 MJH Life Sciences

All rights reserved.